Entry Point Capital, LLC Arcus Biosciences, Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 5,004 shares of RCUS stock, worth $89,821. This represents 0.11% of its overall portfolio holdings.
Number of Shares
5,004Holding current value
$89,821% of portfolio
0.11%Shares
1 transactions
Others Institutions Holding RCUS
# of Institutions
207Shares Held
49MCall Options Held
173KPut Options Held
151K-
Black Rock Inc. New York, NY9.76MShares$175 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$94.4 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA4.25MShares$76.2 Million0.65% of portfolio
-
State Street Corp Boston, MA3.06MShares$54.8 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.83MShares$32.9 Million0.08% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.3B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...